Detalhe da pesquisa
1.
Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy.
PLoS Pathog
; 17(7): e1009278, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34228762
2.
Addendum: Immune clearance of highly pathogenic SIV infection.
Nature
; 547(7661): 123-124, 2017 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28636599
3.
In vitro and in vivo characterization of a recombinant rhesus cytomegalovirus containing a complete genome.
PLoS Pathog
; 16(11): e1008666, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33232376
4.
The Role of MHC-E in T Cell Immunity Is Conserved among Humans, Rhesus Macaques, and Cynomolgus Macaques.
J Immunol
; 200(1): 49-60, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29150562
5.
Immune clearance of highly pathogenic SIV infection.
Nature
; 502(7469): 100-4, 2013 Oct 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-24025770
6.
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine.
Nature
; 473(7348): 523-7, 2011 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-21562493
7.
Late gene expression-deficient cytomegalovirus vectors elicit conventional T cells that do not protect against SIV.
JCI Insight
; 8(6)2023 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36749635
8.
Myeloid cell tropism enables MHC-E-restricted CD8+ T cell priming and vaccine efficacy by the RhCMV/SIV vaccine.
Sci Immunol
; 7(72): eabn9301, 2022 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35714200
9.
Cytomegalovirus-vaccine-induced unconventional T cell priming and control of SIV replication is conserved between primate species.
Cell Host Microbe
; 30(9): 1207-1218.e7, 2022 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35981532
10.
Cytomegaloviral determinants of CD8+ T cell programming and RhCMV/SIV vaccine efficacy.
Sci Immunol
; 6(57)2021 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33766849
11.
Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy.
Science
; 372(6541)2021 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33766941
12.
Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity.
Sci Transl Med
; 11(501)2019 07 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31316006
13.
Characterization of a live-attenuated HCMV-based vaccine platform.
Sci Rep
; 9(1): 19236, 2019 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31848362
14.
A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge.
Sci Transl Med
; 11(501)2019 07 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31316007
15.
Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound.
Nat Med
; 24(9): 1430-1440, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30082858
16.
Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine.
Nat Med
; 24(2): 130-143, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29334373
17.
Broadly targeted CD8⺠T cell responses restricted by major histocompatibility complex E.
Science
; 351(6274): 714-20, 2016 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26797147
18.
Cytomegalovirus pp65 limits dissemination but is dispensable for persistence.
J Clin Invest
; 124(5): 1928-44, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24691437
19.
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms.
Science
; 340(6135): 1237874, 2013 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23704576